secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001213900-22-079246
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Pharmaceuticals' auditor KPMG resigns; Marcum appointed as successor
--------------------------------------------------------------------------

- KPMG resigned as independent auditor on Dec 8, 2022, declining to stand for reelection; no disagreements on accounting matters.
- KPMG's FY2022 and FY2021 audit reports included a going-concern paragraph citing substantial doubt about InMed's ability to continue.
- InMed had an unremediated material weakness in internal control over financial reporting as of June 30, 2022.
- Audit Committee appointed Marcum LLP as new auditor on Dec 11, 2022, subject to standard client acceptance procedures.
- No consultations with Marcum before engagement on accounting or audit matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022079246/0001213900-22-079246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390022079246/ea170063-8k_inmedpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-079246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer